— Know what they know.
Not Investment Advice

PTHS

Pelthos Therapeutics Inc.
1W: -14.5% 1M: -11.4% 3M: -23.1% YTD: -30.1%
$20.59
-1.41 (-6.41%)
After Hours: $23.00 (+2.41, +11.70%)
AMEX · Healthcare · Biotechnology · $13.4M · Alpha Radar Neutral · Power 48
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$13.4M
52W Range9-54.29
Volume3,740
Avg Volume10,567
Beta3.94
Dividend
Analyst Ratings
3 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOScott Plesha
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2025-07-02
4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703
Durham, NC 27703
US
877 265 8266
About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Recent Insider Trades

NameTypeSharesPriceDate
LIGAND PHARMACEUTICA D-Return 0 $34.44 2025-12-17
LIGAND PHARMACEUTICA A-Award 0 $29.73 2025-12-17
Pauls Matthew G-Gift 9,542 2025-12-10
Friedberg Ezra M S-Sale 5,999 $28.00 2025-11-25
Friedberg Ezra M S-Sale 2,000 $28.14 2025-11-25

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms